Remote patient monitoring company, Withings Health Solutions, a division of Withings, announced the release of BPM Pro 2, a cellular blood pressure monitor.
The blood pressure monitor includes a Patient Insights feature that aims to simplify clinical workflows by collecting critical data via the device, including symptoms and medication adherence. Additionally, care teams have the capability to send patients customized messages and reminders.
Data is immediately synced through cellular connectivity that allows healthcare partners to access the patient-generated data via their personal clinical platform or Withings proprietary patient-monitoring platform. It also offers WiFi and Bluetooth connectivity options.
In addition to measuring heart rate and blood pressure, BPM Pro 2 is intended to have a future ability to take a 1-lead ECG to detect atrial fibrillation.
According to the company, the portable device is compact and user-friendly. It supports two cuff sizes (9 to 17 inches and 16 to 21 inches), and displays blood pressure readings and other information in bold text, and in color.
The device also includes a symptom-tracking feature whereby patients are asked customized questions to capture information like symptoms, medication adherence and sleep patterns.
It can be structured to automatically cue patients to retake their blood pressure if it reaches a specific predetermined threshold.
The device will be available in November, when the company expects FDA clearance.
“At-home blood pressure monitoring has become a standard across the industry for managing chronic conditions like hypertension and heart failure but poses a real challenge in making sure the data collected is consistent, reliable, and actionable for care teams,” Aline Criton, chief clinical and regulatory affairs officer at Withings, said in a statement.
“Elevated readings may result from simple factors like improper rest before a measurement or signal more serious issues such as the start of a hypertensive crisis. BPM Pro 2 addresses these challenges with advanced features that enhance data reliability, and provide contextual patient insights that help care teams differentiate between routine variations and critical health events allowing for more timely and personalized care intervention.”
THE LARGER TREND
In September, Withings secured FDA clearance with Sleep Rx Mat, a contactless device designed to diagnose sleep apnea at home. Sleep Rx Mat provides detailed analysis of sleep, breathing and cardiovascular activity all through the night.
Last year, the company launched U-Scan, a biomarker assessment platform that can be put inside a toilet bowl to monitor someone’s health via urine analysis. U-Scan is a reader with changeable analysis cartridges that examines urine for specific biomarkers and forwards insights to the Withings Health Mate app daily.
In 2022, Withings unveiled Sleep Analyzer, an under-the-mattress sleep-tracking mat designed to detect sleep apnea.
That same year, Medable partnered with Withings Health Solutions to use the company’s connected devices for decentralized clinical trials. The alliance allowed Withings’ tools for remote monitoring, like connected scales, blood pressure monitors and sleep-tracking mats, to gather patient data and combine with Medable’s clinical trial platform.
